
Loading, please wait...

Loading, please wait...

Colorectal cancer remains a leading cause of global cancer-related mortality. For decades, oncologists viewed platelets primarily as physiological guardians of hemostasis and vascular repair. However, emerging molecular evidence demonstrates that platelets in colorectal cancer actively drive tumor initiation, local progression, and distant dissemination. Malignant cells systematically hijack thrombocytic pathways to shield themselves from mechanical stress and immune clearance. Consequently, platelets orchestrate a complex pro-tumorigenic microenvironment that accelerates disease progression.
Platelets do not merely circulate as passive fragments in malignancy. Instead, they establish dynamic reciprocal communication with colorectal adenocarcinoma cells. When malignant epithelial cells breach mucosal basements, they directly encounter blood platelets. In response, colorectal tumor cells activate platelets through surface-bound tissue factor and adenosine diphosphate signaling. Activated platelets immediately degranulate, releasing critical growth factors such as vascular endothelial growth factor. Furthermore, these dense granules secrete transforming growth factor-beta, which profoundly alters cellular behavior. As a result, local tumor proliferation accelerates rapidly within the intestinal wall. In addition, activated platelets deposit a rich fibrin meshwork around circulating tumor cells. This protective cloak shields malignant cells against lethal hemodynamic shear forces in the circulation. Moreover, this aggregation prevents immune-mediated lysis by natural killer cells. Therefore, platelets serve as indispensable mechanical bodyguards that sustain malignant survival during transit. Clinicians now appreciate that elevated platelet counts often correlate with advanced clinical staging in colorectal cancer. Consequently, platelet activation represents a key hallmark of systemic tumor progression.
Among platelet adhesion molecules, P-selectin, also designated as CD62P, plays a pivotal role in metastatic colonization. Resting platelets strictly sequester CD62P inside internal alpha-granules. However, upon exposure to thrombin or malignant contact, platelets rapidly mobilize CD62P to their external membrane surface. There, CD62P binds specifically to sialylated carbohydrate ligands expressed on colorectal cancer cells. This rapid molecular tethering facilitates firm platelet-tumor microaggregates within the bloodstream. Furthermore, CD62P engages endothelial ligands, anchoring the circulating tumor aggregates to vascular endothelium in distant capillary beds. Consequently, this biological adhesive bridge allows malignant cells to extravasate through vessel walls into hepatic and pulmonary parenchyma. Beyond mechanical arrest, CD62P signaling orchestrates profound local immunomodulation. For example, CD62P interactions actively polarize tumor-infiltrating macrophages toward an immunosuppressive M2 phenotype. These polarized macrophages suppress cytotoxic T lymphocytes and produce potent pro-angiogenic factors. In addition, CD62P stimulates local endothelial cells to secrete inflammatory chemokines that recruit myeloid-derived suppressor cells. Thus, CD62P functions as a physical tether and an architect of an immune-tolerant metastatic niche.
Another decisive molecular axis involves the C-type lectin-like receptor-2, commonly known as CLEC-2. Circulating platelets express CLEC-2 at high physiological density. Interestingly, CLEC-2 interacts with its endogenous ligand, podoplanin, a transmembrane glycoprotein upregulated in aggressive colorectal cancers. When circulating platelets contact podoplanin-positive colorectal cancer cells, CLEC-2 initiates robust intracellular signaling cascades. Specifically, this ligation triggers tyrosine phosphorylation through spleen tyrosine kinase and phospholipase C gamma two pathways. Consequently, platelets undergo intense activation and aggregation independent of conventional thrombin pathways. Moreover, this distinct signaling cascade induces cancer cells to undergo epithelial-mesenchymal transition. Through this phenotypic shift, tumor cells lose epithelial polarity, shed E-cadherin, and gain enhanced migratory competence. In addition, the CLEC-2 and podoplanin interaction triggers localized thrombus formation around invading tumor borders. This microvascular thrombosis promotes intratumoral hypoxia, which further accelerates hypoxia-inducible factor expression. Therefore, the CLEC-2 axis simultaneously amplifies cellular invasiveness, tissue remodeling, and cancer-associated thrombosis. Targeting this specific platelet-tumor axis offers exciting possibilities to disconnect malignant progression from physiological clotting.
Platelets actively reprogram the broader colorectal tumor microenvironment through diverse paracrine signals. Colorectal tumors constantly recruit platelets to stromal margins via specific chemokine gradients. Once recruited, platelets release dense reserves of transforming growth factor-beta and platelet factor four into the stroma. Consequently, these potent biochemical mediators stimulate quiescent fibroblasts into active cancer-associated fibroblasts. These cancer-associated fibroblasts synthesize dense collagen bundles, creating a rigid extracellular matrix that impedes chemotherapy delivery. Furthermore, platelets directly dismantle antitumor immunity through multiple coordinated mechanisms. For instance, platelets shed functional major histocompatibility complex molecules onto malignant surfaces, masking tumor antigens from immunosurveillance. In addition, platelet-derived transforming growth factor-beta directly suppresses the cytolytic function of natural killer cells and CD8-positive T lymphocytes. Moreover, platelets release adenosine and prostaglandin E2, which hinder dendritic cell maturation and impair antigen presentation. As a result, the tumor successfully evades immunological destruction and continues uninhibited expansion. Thus, platelets act as critical biochemical architects that construct an immunosuppressive sanctuary within colorectal tissue.
The multidimensional involvement of platelets in colorectal malignancy creates compelling opportunities for innovative therapy. Historically, clinicians utilized low-dose aspirin to reduce colorectal adenoma recurrence and decrease overall cancer incidence. Observational trials clearly demonstrate that aspirin suppresses cyclooxygenase-one activity, limiting platelet-derived thromboxane A2 production. However, long-term nonsteroidal therapy carries notable risks of gastrointestinal ulceration and systemic hemorrhage. Therefore, modern oncology research focuses on developing selective inhibitors that target specific tumor-platelet interactions without disrupting physiological hemostasis. Monoclonal antibodies and small molecules targeting CD62P effectively disrupt platelet-tumor adhesion in preclinical models. Similarly, novel small-molecule inhibitors blocking the CLEC-2 and podoplanin binding interface show impressive antimetastatic efficacy. These targeted agents significantly reduce hematogenous spread while preserving essential coagulation pathways. Furthermore, combining platelet-directed antagonists with modern immune checkpoint inhibitors shows promising synergistic potential. By stripping the protective platelet shield from circulating tumor cells, immunotherapy can more effectively eradicate microscopic metastatic deposits. Ultimately, deciphering the exact molecular cross-talk between platelets and colorectal cancer will usher in safer targeted regimens.
Platelets facilitate hematogenous metastasis by forming protective microaggregates around circulating colorectal cancer cells. This physical cloaking shields malignant cells from lethal fluid shear stress and cytotoxic natural killer cell surveillance. Furthermore, platelet surface receptors like P-selectin mediate firm adhesion to vascular endothelial walls in distant organs. Platelets subsequently release permeabilizing factors that loosen endothelial junctions. Consequently, tumor cells efficiently extravasate across capillary barriers into secondary metastatic sites such as the liver.
The CLEC-2 and podoplanin axis triggers non-canonical platelet activation when platelet CLEC-2 binds podoplanin on invasive colorectal cells. This molecular interaction activates downstream spleen tyrosine kinase pathways, precipitating platelet aggregation and microthrombus formation. Additionally, this signaling cascade promotes epithelial-mesenchymal transition in colorectal cancer cells, enhancing their invasive and migratory potential. Moreover, the resulting microvascular thrombosis induces localized hypoxia, which further accelerates tumor aggressiveness and elevates cancer-associated thrombosis risks.
Clinicians currently explore antiplatelet strategies alongside conventional chemotherapy and immunotherapy with great caution. While low-dose aspirin demonstrates clear preventive benefits, it introduces measurable bleeding complications during aggressive cytotoxic treatment. Consequently, modern investigative drug development prioritizes selective molecular targets such as CD62P or CLEC-2. These precision agents disrupt tumor-platelet interactions and reverse immunosuppression without impairing baseline hemostatic clot formation, offering a significantly safer therapeutic window for future clinical application.
Disclaimer: This content is for informational and educational purposes only... Refer to the latest local and national guidelines for clinical practice.
References

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


Platelets actively influence colorectal cancer progression beyond hemostasis. Key surface receptors like P-selectin (CD62P) and CLEC-2 promote tumor cell extravasation, epithelial-mesenchymal transition, and immune evasion, opening promising avenues for targeted antiplatelet therapies in oncology.
Today

A systematic review and meta-analysis of randomized controlled trials evaluates the weight-loss and visceral adiposity outcomes of GLP-1 receptor agonists in reproductive-age women with overweight or obesity and polycystic ovary syndrome, emphasizing clinical benefits alongside current evidence limitations.
Today

A landmark SEER-Medicare study clarifies the breast cancer screening benefit in women aged 70 and 75. Life-years gained vary significantly based on comorbidity, frailty, and race, highlighting why physicians must personalize screening decisions rather than relying solely on arbitrary chronological age cutoffs.
Today

A new scoping review and expert consensus establish a concise 16-measure performance bundle for hospital cardiology services. Covering clinical processes, outcomes, patient-reported experiences, and structural factors, this framework advances value-based cardiovascular care under universal health coverage.
Today

A paired cadaveric study compared triple and quintuple percutaneous Achilles tendon lengthening. While quintuple hemisection showed numerically greater elongation, differences were not statistically significant.
Today

Partial adrenalectomy for pheochromocytoma provides near 100% cure rates while preserving adrenal function in hereditary cases like VHL and MEN2. Despite a 13-15% local recurrence rate, it prevents lifelong steroid dependence without increasing mortality when supported by structured surveillance.
Today